Table 3.
Model features and associated hazard ratios with confidence intervals.
| Model feature | Median HR | 5th percentile HR | 95th percentile HR |
|---|---|---|---|
|
Patient characteristics (statistically significant) | |||
| Death from other cause | 0.0541 | 0.0286 | 0.0788 |
| Chronic liver disease | 0.472 | 0.214 | 0.821 |
| Chronic heart disease | 0.484 | 0.323 | 0.75 |
| Solid organ transplant | 0.577 | 0.217 | 0.983 |
| Body mass index | 1.808 | 1.169 | 2.821 |
|
Disease characteristics (statistically significant) | |||
| Serum IgM level | 0.519 | 0.303 | 0.834 |
| Hemoglobin | 0.554 | 0.35 | 0.931 |
| IgG subtype | 0.621 | 0.415 | 0.856 |
| Calcium | 0.633 | 0.406 | 0.946 |
| IgM subtype | 1.618 | 1.106 | 2.561 |
| IgA subtype | 1.814 | 1.24 | 2.7 |
| Serum M-spike | 4.931 | 2.908 | 10.245 |
|
Medications (statistically significant) | |||
| Multivitamin | 0.495 | 0.345 | 0.706 |
| Immunosuppression | 0.589 | 0.289 | 0.956 |
| Non-coronary NSAID | 0.614 | 0.412 | 0.856 |
| Proton pump inhibitor | 0.626 | 0.429 | 0.889 |
| Vitamin D supplementation | 0.675 | 0.47 | 0.928 |
| Opioid | 0.676 | 0.471 | 0.935 |
| Statin | 0.682 | 0.48 | 0.973 |
| Beta blocker | 0.742 | 0.521 | 0.972 |
|
Patient characteristics (non-significant) | |||
| Black race | 0.497 | 0.194 | 1 |
| Diabetes | 0.743 | 0.497 | 1.064 |
| Autoimmune disease | 0.789 | 0.386 | 1.3 |
| White race | 0.88 | 0.535 | 1.642 |
| History of bacteremia | 1 | 0.802 | 1.345 |
| American Indian race | 1 | 1 | 1 |
| Pacific Islander race | 1 | 1 | 1 |
| Other race | 1 | 1 | 1 |
| Asian race | 1 | 0.965 | 9.281 |
| Race Unknown | 1 | 1 | 1 |
| Chronic kidney disease | 1.067 | 0.674 | 1.639 |
| Male | 1.254 | 0.921 | 1.754 |
| Age at diagnosis | 1.442 | 0.802 | 2.285 |
|
Disease characteristics (non-significant) | |||
| Serum IgA level | 0.713 | 0.441 | 1.106 |
| Serum IgG level | 0.768 | 0.463 | 1.384 |
| Serum albumin level | 0.889 | 0.584 | 1.365 |
| Serum creatinine | 0.972 | 0.587 | 1.622 |
| Beta 2 glycoprotein | 1.035 | 0.612 | 1.986 |
| Serum kappa level | 1.12 | 0.699 | 2.063 |
| Serum kappa/lambda ratio | 1.4227 | 0.88 | 2.611 |
| Serum lambda level | 1.504 | 0.88 | 2.611 |
|
Medications (non-significant) | |||
| Testosterone supplementation | 0.673 | 0.223 | 1.295 |
| Thyroid supplementation | 0.715 | 0.471 | 1.03 |
| Folic acid | 0.747 | 0.502 | 1.048 |
| ACE inhibitor | 0.782 | 0.54 | 1.105 |
| Metformin | 0.848 | 0.488 | 1.296 |
| Rituximab | 0.85 | 0.369 | 1 |
| Aldosterone antagnoist | 0.915 | 0.554 | 1.303 |
| Estrogen supplementation | 1 | 0.663 | 1.668 |
| Corticosteroid | 1.014 | 0.678 | 1.412 |
| Therapeutic dose anticoagulant | 1.073 | 0.759 | 1.429 |
| Antiplatelet medication | 1.119 | 0.799 | 1.522 |
| Loop diuretic | 1.299 | 0.926 | 1.801 |
| Myelodysplastic syndrome drug | 1.858 | 0.722 | 5.174 |